XAIR earnings: next report 2026-08-11, real EPS beat/miss history, analyst consensus Buy, P/E -0.06. Updated 2026-07-23.
Beyond Air (XAIR) Research Hub
Beyond Air (XAIR) trades on NASDAQ, US in the Healthcare (Medical - Devices) sector. As of 2026-09-11, shares last closed at 3.2 USD (+0.63%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.06, market cap 0.00B. This hub links to the full technical, earnings and options research available for XAIR.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Medical - Devices) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 3.2 USD (+0.63%) |
| 52-week range | 3.095 USD – 10.5 USD |
| Trend regime | Range |
| 14-day RSI | 29.7 (Oversold) |
| Trailing P/E | -0.06 |
| Market cap | 0.00B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-11 |
Available research for XAIR
Covered Call on XAIR: how it works, illustrative setup around the real 3.2 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on XAIR: how it works, illustrative setup around the real 3.2 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on XAIR: how it works, illustrative setup around the real 3.2 USD price, max profit/loss, breakeven and when to use it. Educational.
XAIR technical analysis: range, last 3.2 USD, RSI 29.7, 52w range 3.095 USD–10.5 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is XAIR in?
Beyond Air (XAIR) is classified under Healthcare (Medical - Devices), listed on NASDAQ, US.
Is XAIR in an uptrend or downtrend?
As of 2026-09-11, XAIR is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is XAIR's trailing P/E ratio?
XAIR's trailing P/E is -0.06, with a market cap of 0.00B. See the earnings research page for full valuation detail.
When does XAIR next report earnings?
XAIR is next scheduled to report earnings on 2026-08-11, with a consensus EPS estimate of -10.1 USD.